13 assets in Pancreatic Acinar Cell Carcinoma

Therapeutic assets addressing Pancreatic Acinar Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Pancreatic Acinar Cell Carcinoma	Artios Pharma Ltd	P2	BB (71)
Cis-Diamminedichloroplatinum Ii Pancreatic Acinar Cell Carcinoma	Alliance for Clinical Trials in Oncology	P2/3	B (57)
Ipilimumab Pancreatic Acinar Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Pancreatic Acinar Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Olaparib Pancreatic Acinar Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Alnodesertib Pancreatic Acinar Cell Carcinoma	Artios Pharma Ltd	P1/2	CCC (48)
Vismodegib Pancreatic Acinar Cell Carcinoma	Mayo Clinic	P1	CC (47)
Aquocobalamin Pancreatic Acinar Cell Carcinoma	General Oncology, Inc.	P1	CC (43)
Camustine Pancreatic Acinar Cell Carcinoma	General Oncology, Inc.	P1	CC (43)
Falimarev Pancreatic Acinar Cell Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Inalimarev Pancreatic Acinar Cell Carcinoma	National Cancer Institute (NCI)	P1	CC (43)
Melphalan Pancreatic Acinar Cell Carcinoma	General Oncology, Inc.	P1	CC (43)
Sargramostim Pancreatic Acinar Cell Carcinoma	National Cancer Institute (NCI)	P1	CC (43)